Webinar Date/Time: Tuesday, October 24th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Industry-wide, clinical trial protocols continue to increase in complexity over time. This webinar adds to the growing evidence of which elements of trial design and strategy correlate with lower study recruitment, increased timelines, and cost to help mitigate their potential impact during protocol development.
Register Free: https://www.pharmexec.com/pe_w/protocol-design-complexity
Event Overview:
Industry-wide, clinical trial protocols continue to increase in complexity over time. This webinar adds to the growing evidence of which elements of trial design and strategy correlate with lower study recruitment, increased timelines, and cost.
Connecting protocol complexity with trial outcomes provides insight to allow for better designed protocols that sites and patients want to participate in. Consequently, there is less potential for operational errors resulting in deviations and amendments and efficacy and safety is determined more efficiently, moving potential treatments more swiftly to patients who need them.
Three key take-aways
In this webinar, data science experts will present:
Speakers:
Denise Messer
Design Analytics Director
IQVIA
Denise Messer is a design analytics director at IQVIA. She has over 25 years of experience in research and clinical trials, including expertise in clinical trial planning and design. She has spoken at conferences and has been published in industry journals covering topics such as assessing and scoring trial patient burden, highlighting the voice of the patient in trial design, and assessing protocol complexity.
At IQVIA, she helped develop the IQVIA Data-informed Protocol Assessment (DIPA), using data to highlight areas for protocol optimization before operationalization, including creation of a patient burden algorithm and protocol scoring benchmarks.
Steven Zhang
Global Analytics Manager
IQVIA
Steven Zhang is a global analytics manager at IQVIA. He has more than seven years of experience in the Healthcare Tech industry, with a strong expertise in data science and machine learning. He started his career working on leveraging AI to personalize treatment selection in depression.
As a data scientist for this IQVIA project, he was responsible for the data processing and exploration regarding both the enrollment strategy and operational metrics. Combined with insights on clinical trial protocols, Steven analyzed what factors from protocols contribute to complexity and their impact on study benchmarks such as cycle times and other trial performance outcomes.
Steven holds a Master of Science degree in Neuroscience from McGill University.
Register Free: https://www.pharmexec.com/pe_w/protocol-design-complexity
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.